March 13th, 2022 (Earnings Report) Dear Reader, We just identified several healthtech stocks that are expected to release earnings this week. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Altimmune
Symbol: ALT
Recent Price: $6.96
Average Analyst Price Target: $27.33 (292.67%)
Market Cap: $276.58M
Last Year's EPS: -$0.17
Consensus EPS Forecast: -$0.66
Expected Earnings Date: Mar 14 2022
Recent Analyst Action: Seamus Fernandez, analyst at Guggenheim, reiterates coverage on Altimmune (ALT) in the Healthcare sector with a Buy rating and a price target of n/a (1 month ago).
TipRanks.com also reports that Altimmune currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $27.33 . The target pricing ranges from a high forecast of $31.00 down to a low forecast of $21.00. Altimmune (ALT)’s last closing price was $6.96 which would put the average price target at 292.67% upside.Here are 3rd party ratings for ALT:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Bottom 34% (164 out of 249)
--------------------------------------------------------------------------
Gamida Cell
Symbol: GMDA
Recent Price: $3.66
Average Analyst Price Target: $15.50 (323.50%)
Market Cap: $217.03M
Last Year's EPS: -$0.64
Consensus EPS Forecast: -$0.41
Expected Earnings Date: Mar 14 2022
Recent Analyst Action: Vernon Bernardino, analyst at H.C. Wainwright, reiterates coverage on Gamida Cell (GMDA) in the Healthcare sector with a Buy rating and a price target of $ 22 (1 month ago).
TipRanks.com also reports that Gamida Cell currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $15.50 . The target pricing ranges from a high forecast of $22.00 down to a low forecast of $11.00. Gamida Cell (GMDA)’s last closing price was $3.66 which would put the average price target at 323.50% upside.Here are 3rd party ratings for GMDA:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Buy, Bottom 36% (159 out of 249)
--------------------------------------------------------------------------
IDEAYA Biosciences
Symbol: IDYA
Recent Price: $12.8
Average Analyst Price Target: $28.67 (123.98%)
Market Cap: $492.77M
Last Year's EPS: -$0.18
Consensus EPS Forecast: -$0.31
Expected Earnings Date: Mar 14 2022
Recent Analyst Action: Benjamin Burnett, analyst at Stifel Nicolaus, reiterates coverage on IDEAYA Biosciences (IDYA) in the Healthcare sector with a Buy rating and a price target of $ 20 (5 days ago).
TipRanks.com also reports that IDEAYA Biosciences currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $28.67 . The target pricing ranges from a high forecast of $34.00 down to a low forecast of $20.00. IDEAYA Biosciences (IDYA)’s last closing price was $12.8 which would put the average price target at 123.98% upside.Here are 3rd party ratings for IDYA:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Bottom 36% (159 out of 249)
--------------------------------------------------------------------------
Infinity Pharma
Symbol: INFI
Recent Price: $0.9181
Average Analyst Price Target: $8.25 (798.59%)
Market Cap: $81.73M
Last Year's EPS: -$0.17
Consensus EPS Forecast: -$0.14
Expected Earnings Date: Mar 14 2022
Recent Analyst Action: Kalpit Patel, analyst at B.Riley Financial, reiterates coverage on Infinity Pharma (INFI) in the Healthcare sector with a Buy rating and a price target of n/a (1 month ago).
TipRanks.com also reports that Infinity Pharma currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $8.25 . The target pricing ranges from a high forecast of $9.00 down to a low forecast of $7.50. Infinity Pharma (INFI)’s last closing price was $0.9181 which would put the average price target at 798.59% upside.Here are 3rd party ratings for INFI:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 34% (164 out of 249)
--------------------------------------------------------------------------
Precision BioSciences
Symbol: DTIL
Recent Price: $3.91
Average Analyst Price Target: $21.00 (437.08%)
Market Cap: $237.60M
Last Year's EPS: -$0.44
Consensus EPS Forecast: -$0.47
Expected Earnings Date: Mar 14 2022
Recent Analyst Action: Soumit Roy, analyst at JonesTrading, reiterates coverage on Precision BioSciences (DTIL) in the Healthcare sector with a Buy rating and a price target of $ 23 (3 months ago).
TipRanks.com also reports that Precision BioSciences currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $21.00 . The target pricing ranges from a high forecast of $23.00 down to a low forecast of $20.00. Precision BioSciences (DTIL)’s last closing price was $3.91 which would put the average price target at 437.08% upside.Here are 3rd party ratings for DTIL:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 36% (159 out of 249)
--------------------------------------------------------------------------
Syros Pharmaceuticals
Symbol: SYRS
Recent Price: $1.15
Average Analyst Price Target: $17.67 (1436.52%)
Market Cap: $71.24M
Last Year's EPS: -$0.62
Consensus EPS Forecast: -$0.46
Expected Earnings Date: Mar 14 2022
Recent Analyst Action: Jason Butler, analyst at JMP Securities, reiterates coverage on Syros Pharmaceuticals (SYRS) in the Healthcare sector with a Buy rating and a price target of $ 20 (6 days ago).
TipRanks.com also reports that Syros Pharmaceuticals currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $17.67 . The target pricing ranges from a high forecast of $23.00 down to a low forecast of $10.00. Syros Pharmaceuticals (SYRS)’s last closing price was $1.15 which would put the average price target at 1436.52% upside.Here are 3rd party ratings for SYRS:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 36% (159 out of 249)
--------------------------------------------------------------------------
Tecan Group AG
Symbol: TCHBF
Recent Price: $403.73
Average Analyst Price Target: $636.98 (57.77%)
Market Cap: $5.12B
Last Year's EPS: $5.2
Consensus EPS Forecast: $5.94
Expected Earnings Date: Mar 14 2022
Recent Analyst Action: Maja Pataki, analyst at Kepler Capital , reiterates coverage on Tecan Group AG (TCHBF) in the Healthcare sector with a Buy rating and a price target of $ 684.77 (5 days ago).
TipRanks.com also reports that Tecan Group AG currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $636.98 . The target pricing ranges from a high forecast of $684.77 down to a low forecast of $589.54. Tecan Group AG (TCHBF)’s last closing price was $403.73 which would put the average price target at 57.77% upside.Here are 3rd party ratings for TCHBF:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: n/a, n/a
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com